Home The Word Brain My Amedeo FAQ Privacy About   


CC Journal Club

Our weekly journal club for junior residents and medical students


  Leukemia

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    April 2025
  1. MA XH, Gao MG, Cheng RQ, Qin YZ, et al
    The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression.
    Cancer Lett. 2025;615:217547.
    PubMed     Abstract available


  2. LIU Y, Tu Y, Yan Z, Xiao J, et al
    CAR T-Cell Therapy in Chronic Myeloid Leukemia Patients with Lymphoid Blast Crisis: A Multicenter Clinical Analysis.
    Cancer Lett. 2025 Apr 1:217688. doi: 10.1016/j.canlet.2025.217688.
    PubMed    


    February 2025
  3. CHEN DW, Schrey JM, Wafula EK, Fan JM, et al
    Leukemia confers a durable imprint on healthy hematopoietic stem and progenitor cells.
    Cancer Lett. 2025;616:217590.
    PubMed     Abstract available


  4. LIU C, Liu G, Zhou F, Chen L, et al
    EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis.
    Cancer Lett. 2025;614:217556.
    PubMed     Abstract available


    January 2025
  5. WEISS S, Zdarsky B, Witalisz-Siepracka A, Edtmayer S, et al
    Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia.
    Cancer Lett. 2025;613:217501.
    PubMed     Abstract available


  6. LI M, Li Y, Qu Q, Wang C, et al
    Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cancer Lett. 2025 Jan 11:217460. doi: 10.1016/j.canlet.2025.217460.
    PubMed     Abstract available


  7. PEI HZ, Guo Y, Zhao Y, Zhang D, et al
    FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia.
    Cancer Lett. 2025;611:217446.
    PubMed     Abstract available


    December 2024
  8. WANG J, Ma W, Huang J, Qiu G, et al
    Corrigendum to "HIF-2alpha 1 inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment" [Cancer lett. 597 (2024) 217060].
    Cancer Lett. 2024 Dec 31:217435. doi: 10.1016/j.canlet.2024.217435.
    PubMed    


  9. JIN P, Shen J, Zhao M, Yu J, et al
    Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy.
    Cancer Lett. 2024 Dec 24:217427. doi: 10.1016/j.canlet.2024.217427.
    PubMed     Abstract available


  10. VAN TRIMPONT M, Schalk AM, Hofkens K, Peeters E, et al
    A human-like glutaminase-free asparaginase is highly efficacious in ASNS(low) leukemia and solid cancer mouse xenograft models.
    Cancer Lett. 2024 Dec 19:217404. doi: 10.1016/j.canlet.2024.217404.
    PubMed     Abstract available


    November 2024
  11. WANG Y, Chang YJ, Chen J, Han M, et al
    Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.
    Cancer Lett. 2024;605:217264.
    PubMed     Abstract available


  12. HLOZKOVA K, Vasylkivska M, Boufersaoui A, Marzullo B, et al
    Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase.
    Cancer Lett. 2024;605:217242.
    PubMed     Abstract available


    October 2024
  13. WANG ZK, Zhang ZW, Lyu ZS, Xing T, et al
    Inhibition of TGF-beta signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients.
    Cancer Lett. 2024;605:217290.
    PubMed     Abstract available


    August 2024
  14. WANG YQ, Ren Y, Gale RP, Niu LT, et al
    Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells.
    Cancer Lett. 2024 Aug 5:217158. doi: 10.1016/j.canlet.2024.217158.
    PubMed     Abstract available


    July 2024
  15. LIU T, Gu L, Mui A, Wu Z, et al
    An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues.
    Cancer Lett. 2024 Jul 23:217126. doi: 10.1016/j.canlet.2024.217126.
    PubMed     Abstract available


  16. LIU Y, Zheng L, Li Y, Ma L, et al
    Neratinib impairs function of m6A recognition on AML1-ETO pre-mRNA and induces differentiation of t (8;21) AML cells by targeting HNRNPA3.
    Cancer Lett. 2024;594:216980.
    PubMed     Abstract available


  17. YAN N, Wang ZL, Wang XJ, Gale RP, et al
    Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
    Cancer Lett. 2024;598:217104.
    PubMed     Abstract available


  18. YAO M, Jiang X, Xiao F, Lv X, et al
    Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance.
    Cancer Lett. 2024;593:216949.
    PubMed     Abstract available


    June 2024
  19. WANG J, Ma W, Huang J, Qiu G, et al
    HIF-2alpha Inhibition Disrupts Leukemia Stem Cell Metabolism and Impairs Vascular Microenvironment to Enhance Chronic Myeloid Leukemia Treatment.
    Cancer Lett. 2024 Jun 14:217060. doi: 10.1016/j.canlet.2024.217060.
    PubMed     Abstract available


  20. YUAN J, Zhang J, Zhao B, Liu F, et al
    Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.
    Cancer Lett. 2024 Jun 4:217018. doi: 10.1016/j.canlet.2024.217018.
    PubMed     Abstract available


    May 2024
  21. XU M, Li S
    The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.
    Cancer Lett. 2024;593:216969.
    PubMed     Abstract available


  22. WANG D, He J, Liu S, Zhang H, et al
    Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia.
    Cancer Lett. 2024 May 17:216970. doi: 10.1016/j.canlet.2024.216970.
    PubMed     Abstract available


  23. TAN Y, Xin L, Wang Q, Xu R, et al
    FLT3-Selective PROTAC: Enhanced Safety and Increased Synergy with Venetoclax in FLT3-ITD Mutated Acute Myeloid Leukemia.
    Cancer Lett. 2024 May 3:216933. doi: 10.1016/j.canlet.2024.216933.
    PubMed     Abstract available


    April 2024
  24. ZHAO Y, Chen W, Yu J, Pei S, et al
    TP53 in MDS and AML: Biological and clinical advances.
    Cancer Lett. 2024;588:216767.
    PubMed     Abstract available


  25. SUN H, Xie Y, Wu X, Hu W, et al
    circRNAs as prognostic markers in pediatric acute myeloid leukemia.
    Cancer Lett. 2024;591:216880.
    PubMed     Abstract available


    March 2024
  26. HE Y, Jiang S, Cui Y, Liang J, et al
    Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis.
    Cancer Lett. 2024 Mar 8:216797. doi: 10.1016/j.canlet.2024.216797.
    PubMed     Abstract available


    February 2024
  27. CHENG C, Liang S, Yue K, Wu N, et al
    STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vdelta2(+) T cells in acute myeloid leukemia.
    Cancer Lett. 2024 Feb 13:216730. doi: 10.1016/j.canlet.2024.216730.
    PubMed     Abstract available


    January 2024
  28. YANG F, Cui X, Wang H, Zhang D, et al
    Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS.
    Cancer Lett. 2024 Jan 17:216652. doi: 10.1016/j.canlet.2024.216652.
    PubMed     Abstract available


    December 2023
  29. JUNG YY, Ahn KS, Shen M
    Unveiling autophagy complexity in leukemia: The molecular landscape and possible interactions with apoptosis and ferroptosis.
    Cancer Lett. 2023 Dec 1:216518. doi: 10.1016/j.canlet.2023.216518.
    PubMed     Abstract available


    September 2023
  30. WEN J, Chen Y, Liao C, Ma X, et al
    Engineered mesenchymal stem cell exosomes loaded with miR-34c-5p selectively promote eradication of acute myeloid leukemia stem cells.
    Cancer Lett. 2023 Sep 26:216407. doi: 10.1016/j.canlet.2023.216407.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.